January 30, 2008 - Iroko Pharmaceuticals (Iroko) acquired all non-U.S. commercial rights to Aggrastat (tirofiban HCl) from Merck & Co. Inc., used for patients undergoing coronary angioplasty or atherectomy to prevent cardiac ischemic complications, in a move Iroko hopes will strengthen its presence in the cardiovascular market.

January 30, 2008 - Cardiac Science Corp. won two contracts to supply Powerheart automated external defibrillators (AEDs) and program management services to hundreds of locations worldwide, as Cardiac Science aims to market AEDs as accessible defibrillation in the workplace.

The recent Cardiac Science deals are with the following companies:
- CH2M HILL: Cardiac Science signed an exclusive five-year deal to supply Powerheart AEDs and program management services at all of CH2M HILL locations in the U.S. CH2M HILL has more than 23,000 employees in offices around the world.

January 30, 2008 - TopSpin Medical Inc. installed the Cathamaran Intravascular MRI System at ZOL Hospital in Belgium, marking the first installation of the system and its entrance in a study on vulnerable plaque.

January 30, 2008 - NightHawk Radiology is the exclusive radiology provider for the High-Risk Plaque Initiative, called the HRP Initiative, a research effort aiming to interpret CT Chest scans to identify clinically significant cardiac and nonardiac findings where the participant might benefit from its detection and follow-up.

January 30, 2008 - TopSpin Medical Inc. announced the first commercial installation of the Cathamaran Intravascular MRI System at ZOL Hospital, Genk, Belgium, with the first procedures performed on Jan. 16.

February 2008 - The body regulates its core temperature by reducing the blood flow to the extremities, but anesthesia interferes with this process and affects the temperature control center in the hypothalamus, allowing the normal temperature control limits to be increased and compromising the body's normal response to cold. For these reasons clinicians need to warm patients in the OR, and there are a variety of products available.

January 29, 2008 - Edwards Lifesciences Corp. received conditional approval from the FDA for the addition of the Ascendra transapical delivery system to the U.S. pivotal clinical trial of the Edwards SAPIEN transcatheter aortic heart valve technology.

The FDA also granted permission to Edwards to increase its trial sample size from 600 patients to 1,040 patients. These approvals enable Edwards to address a larger population of patients who may have few or no options for treatment of their heart valve disease.

January 29, 2008 - The Medicines Company received the European Commission�s authorization of an expanded use for Angiox (bivalirudin) in adult patients with acute coronary syndromes (ACS), specifically patients with unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI) planned for urgent or early intervention, when used with aspirin and clopidogrel.

January 28, 2008 - A new multi-center, international clinical trial that compares the safety and effectiveness of thoracic endovascular aortic repair (TEVAR) to open surgery for descending thoracic aortic aneurysms (TAA), indicates that TEVAR (the less invasive endovascular graft) is a promising treatment option for many patients.

January 29, 2008 � A novel treatment for blood clots in the legs, in which injecting or �lacing� the clot with a fiber-binding thrombolytic agent effectively treats deep vein thrombosis (DVT) and reduces the risk of subsequent recurrence or bleeding, according to a pilot study published in the February issue of Radiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now